In this Life Science Leader article, Matt Sussman discusses important steps to take when preparing for a third party drug price evaluation. Sussman notes that determining fair and reasonable drug prices in the U.S. has long been a source of debate as the U.S. has lacked consistent, independent economic analysis to assess the value of new drugs. But now, the Institute for Clinical and Economic Review (ICER) is on the scene and gaining traction. In order to successfully prepare for and mitigate an ICER review, manufacturers must consider taking several important steps to optimize success.
Click here to read the article on Life Science Leader.